Rigel (RIGL) delivered earnings and revenue surprises of -14.29% and 0.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Also with me are David A. Santos, our Chief Commercial Officer; Lisa Rojkjaer, our Chief Medical Officer; and Dean L. Schorno, our Chief Financial Officer. On today's call, I will provide an overview ...

Greetings, and welcome to the Rigel Pharmaceuticals Financial Conference Call for the Fourth Quarter and Full Year 2025. [Operator Instructions] As a reminder, this conference is being recorded. It is ...

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 ...

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million 2025 ...

BAUERTEK Farmaceutical Technologies general manager Richard Nixon Gomez and company president Rigel Gomez attended the ...

Rigel Pharmaceuticals (RIGL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus ...

Cardiovascular technology leader to scale U.S. operations through iRemedy’s AI-powered supply chain platform Our ...

Learn how to finance medical equipment, pros and cons, and more in this medical equipment financing guide for 2026. NEW ...

Researchers at Chulalongkorn University are redefining the role of Thai silk by developing silk protein into a versatile platform for medical products, aiming to reduce Thailand’s reliance on imported ...

Have you been paying attention to shares of Rigel Pharmaceuticals (RIGL)? Shares have been on the move with the stock up 73.3% over the past month. The stock hit a new 52-week high of $51.73 in the ...